Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving Average – Here’s Why

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s stock price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $13.58 and traded as high as $14.89. Enanta Pharmaceuticals shares last traded at $14.55, with a volume of 108,435 shares traded.

Analyst Ratings Changes

Several research firms have recently commented on ENTA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, March 26th. They issued a “buy” rating and a $20.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals Price Performance

The firm’s 50 day moving average is $13.58 and its 200 day moving average is $13.16. The firm has a market cap of $422.24 million, a P/E ratio of -4.55 and a beta of 0.99.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. The business had revenue of $18.62 million for the quarter, compared to analyst estimates of $16.14 million. As a group, analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in Enanta Pharmaceuticals by 91.6% during the fourth quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock worth $58,761,000 after acquiring an additional 1,782,745 shares in the last quarter. Farallon Capital Management LLC raised its holdings in Enanta Pharmaceuticals by 30.6% in the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock worth $43,719,000 after buying an additional 650,000 shares during the last quarter. Krensavage Asset Management LLC raised its holdings in Enanta Pharmaceuticals by 30.8% in the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after buying an additional 651,946 shares during the last quarter. Millennium Management LLC raised its holdings in Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after buying an additional 449,945 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in Enanta Pharmaceuticals by 0.8% in the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after buying an additional 6,522 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.